Semaglutide vs Liraglutide

Cadence is the headline difference here. Liraglutide is a daily subcutaneous shot; semaglutide is weekly. Both are GLP-1 agonists with the same broad mechanism, but the half-life difference (about 13 hours for liraglutide, about a week for semaglutide) drives almost every practical difference a reader will notice in a log. A liraglutide log has 7x the injection events of a semaglutide log over the same calendar window, which has real implications for adherence, scar tissue rotation, and the texture of side-effect tracking.

Trial data put semaglutide ahead on absolute weight loss in head-to-head comparisons — STEP-8 reported about 16 percent loss at 68 weeks for semaglutide 2.4 mg weekly versus about 6 percent for liraglutide 3.0 mg daily over the same window. The gap is structural rather than dose-dependent: semaglutide's longer half-life produces steadier receptor occupancy, which is the variable most strongly correlated with weight-loss magnitude in this drug class. Liraglutide is the older, more established option; semaglutide is the more aggressive one on the loss curve.

Titration on liraglutide is daily and incremental — 0.6, 1.2, 1.8, 2.4, 3.0 mg added in weekly steps. Semaglutide titrates through 0.25, 0.5, 1.0, 1.7, 2.4 mg in 4-week steps. The total ramp time is similar (about a month for both to reach a working dose, longer to top dose), but a daily versus weekly cadence changes the shape of the early-weeks log dramatically — daily users see and score side effects 7x as often, which can make liraglutide read as harsher in a log even when the absolute side-effect rate is comparable.

For tracking purposes the two molecules occupy very different ergonomic categories. A weekly shot is one calendar event; a daily shot is a ritual that needs to land in roughly the same window every day. The calculator pages linked below handle the unit math for either, and the dose-per-vial column on the table above shows how a single vial stretches across the two cadences at the example vial size.

For the Semaglutide vs Liraglutide decision specifically, the calendar shape is what most readers underweight. Semaglutide's example vial is 5 mg drawn against 0.25 mg per dose at 1 dose per week. Liraglutide's example vial is 6 mg drawn against 1.2 mg per dose at 7 doses per week. Those four numbers feed every column in the table above; change any one and the semaglutide vs liraglutide comparison shifts with it.

Concentration in this pair: Semaglutide sits at 2.50 mg/mL on the example reconstitution; Liraglutide sits at 2.00 mg/mL on its example. That single ratio is what determines how many U-100 syringe units a given dose of either molecule actually draws, so it is the first thing to confirm before treating any "Semaglutide vs Liraglutide" unit number on the internet as authoritative.

Doses per vial in this matchup work out to roughly 20 for Semaglutide and 5 for Liraglutide at the example dose sizes, with vial-duration windows near 20.0 weeks and 0.7 weeks respectively. Refill cadence follows directly from those windows, which is why the semaglutide vs liraglutide pair shows up in planning conversations more than in pure mechanism conversations.

When readers compare Semaglutide against Liraglutide, the Semaglutide-side mistakes that show up most in logs are: Switching to a new vial of the same peptide and reusing the old unit count without re-running the calculation against the new vial's diluent volume. Storing reconstituted semaglutide at room temperature for hours before refrigerating, especially after a travel day. Dosing twice in the same week after forgetting whether the previous injection was Sunday or Monday — almost always a logging-gap problem, not a math problem. Reading 0.25 mg as 25 units on the syringe regardless of vial concentration. The unit count is not fixed — it depends on the diluent volume. Each of these gets amplified when a reader is also actively comparing against Liraglutide, because muscle memory from one molecule's unit math leaks into the other.

Semaglutide question worth answering up front — How is semaglutide reconstituted? By adding a measured volume of bacteriostatic water to the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves into a clear solution. The exact diluent volume is up to the user; common choices for a 5 mg vial are 1, 2, or 3 mL.

Semaglutide question worth answering up front — How many units of semaglutide are in 0.25 mg? It depends on the concentration of your vial. On a 5 mg vial reconstituted with 2 mL of bacteriostatic water, 0.25 mg is exactly 10 units on a U-100 insulin syringe. On a 5 mg vial reconstituted with 1 mL, the same dose is 5 units.

On the Liraglutide side of the Semaglutide vs Liraglutide decision, the recurring mistakes are: Failing to titrate the dose up slowly. Forgetting to rotate injection sites, leading to skin irritation. Injecting into a muscle instead of the subcutaneous fat layer. Miscalculating the dose when reconstituting a vial. These are not generic dosing slips — they are the ones that compound when Liraglutide is being logged in parallel with Semaglutide.

Liraglutide question worth answering up front — What's the difference between Saxenda and Victoza? Saxenda and Victoza contain the same active ingredient, Liraglutide. However, they are used for different purposes and at different maximum doses. Saxenda is generally used for weight management and has a higher target dose (3.0 mg), while Victoza is primarily used for blood sugar management in type 2 diabetes and has a lower target dose (1.8 mg).

Liraglutide question worth answering up front — Why is Liraglutide injected daily instead of weekly? Liraglutide was designed to last for about 13 hours in the body. A once-daily injection ensures that there is a stable and effective level of the peptide in your system throughout the day. Other GLP-1 agonists, like Semaglutide, were later engineered to last even longer, allowing for a once-weekly dosing schedule.